CHMFL-FLT3-122
CAS No. : 1839150-56-9
| Size | Price | Stock |
|---|---|---|
| 5mg | $280 | In-stock |
| 10mg | $420 | In-stock |
| 25mg | $710 | In-stock |
| 50mg | $995 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-110293 |
| M.Wt: | 471.55 |
| Formula: | C26H29N7O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 125 mg/mL (ultrasonic) |
CHMFL-FLT3-122 is a potent, selective and orally active FLT3 kinase with an IC50 of 40 nM. CHMFL-FLT3-122 shows selectivity for FLT3 over BTK (IC50 of 421 nM) and c-KIT (IC50 of 559 nM) kinases. CHMFL-FLT3-122 induces apoptosis by arresting the cell cycle into the G0/G1 phase[1].
IC50 & Target:IC50: 40 nM (FLT3 kinase), 421 nM (BTK), 559 nM (c-KIT)[1]
In Vitro:CHMFL-FLT3-122 (compound 18) significantly inhibits the proliferation of FLT3-ITD positive acute myeloid leukemia (AML) cancer cell lines MV4-11 (GI50 = 22 nM), MOLM13/14 (GI50 = 21 nM/42 nM)[1].
CHMFL-FLT3-122 (0.03-1 μM; 24 h) could arrest cell cycle progression of these cell lines into the G0/G1 phase and induction of apoptosis[1].
CHMFL-FLT3-122 (0.03-1 μM; 24 h) significantly inhibits FLT3 auto-phosphorylation at Tyr589/591 site, and also inhibits the phosphorylation of Stat5 ERK, AKT and expression of cMYC[1].
In Vivo:CHMFL-FLT3-122 (12.5-50 mg/kg; oral gavage; once a day; for 22 days) could almost completely suppress the tumor progression, and does not significantly affect the mice body weight[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- CHMFL-FLT3-122
- Cat. No.:
- HY-110293
- Quantity:
Your information is safe with us.